LYB

LyondellBasell

$55.84

-4.04%
Nov 20, 2026
Bobby Quantitative Model
LyondellBasell Industries N.V. is one of the world's largest plastics, chemical and refining companies, producing olefins and polyolefins (polyethylene and polypropylene), propylene oxide and its derivatives, oxyfuels, and advanced polymer solutions for packaging, automotive, construction and consumer end markets, following its 2025 exit from the refining business. The company is a scale-driven commodity and specialty chemicals platform whose integrated naphtha and natural gas liquids crackers, global licensing technology business and massive polyolefin capacity give it a cost-curve position rather than a branded-moat identity. The current investor debate centers on whether the industry is finally emerging from what management and press coverage have called one of the longest downturns in chemical history, a thesis complicated by the February 2026 dividend cut, a severe Middle Eastern naphtha supply disruption tied to the Iran/Hormuz conflict, and a Q3 2026 earnings miss that was partly offset by a revenue beat. Bulls point to a sharp sequential profit recovery and a 33.7% one-year share gain, while bears highlight negative trailing earnings, thin gross margins and a still-fragile global petrochemical supply-demand balance.

People also watch

Ecolab

Ecolab

ECL

Analysis
Sherwin-Williams

Sherwin-Williams

SHW

Analysis
Air Products & Chemicals

Air Products & Chemicals

APD

Analysis
PPG Industries

PPG Industries

PPG

Analysis
International Flavors & Fragrances

International Flavors & Fragrances

IFF

Analysis

BobbyInvestment Opinion: Should I buy LYB Today?

Rating: Hold, with a constructive bias toward accumulating on weakness. The core thesis is that LYB is a deep-cyclical commodity chemical producer whose earnings have already inflected sharply off a trough — Q3 2026 net income of $758 million (EPS $2.33) versus a -$892 million loss in Q3 2025 — yet trades at roughly 9.1x the $6.394 consensus forward EPS and 0.46x sales, so the recovery is priced with heavy skepticism rather than enthusiasm. With 13 analysts split between Overweight/Outperform (Wells Fargo, RBC Capital) and Neutral/Equal Weight (UBS, Citigroup, Barclays) and no published consensus target, the institutional stance is cautiously neutral-to-constructive, consistent with a Hold rather than a conviction Buy.

Supporting evidence is genuinely two-sided. On the positive side: forward EPS of $6.394 against $58.46 implies ~9.1x earnings; Q3 2026 free cash flow of $1.413 billion on a $13.9 billion market cap annualizes to a ~17% FCF yield (though TTM FCF of $2.414 billion is inflated by working-capital swings, with Q1 2026 at -$538 million); revenue grew 9.99% year-over-year to $8.499 billion; and price-to-book of 1.38x and price-to-sales of 0.46x sit at the bottom of the stock's own multi-year band (PS was 3.60x in Q1 2026). On the negative side: trailing EPS is -$0.053 with a -2.46% net margin and -7.37% ROE; gross margin swung from 9.74% (Q1 2026) to 22.21% (Q2) to 17.60% (Q3); debt-to-equity is 1.58x with EV/EBITDA at 22.33x; and the February 2026 dividend cut, with a payout ratio of -2.37, showed cash returns are not secure.

The biggest risks that could invalidate the thesis are (1) a renewed downturn in global polyolefin demand that pulls gross margin back toward Q1's 9.74%, (2) a fresh feedstock shock of the kind seen in March 2026 when the Iran/Hormuz conflict disrupted Middle Eastern naphtha, and (3) the stock's momentum breakdown — down 14.16% over three months versus the S&P 500's -4.25%, with -9.91% relative strength. This Hold would upgrade to Buy if gross margin holds above 17% for two consecutive quarters and forward EPS estimates migrate toward the $7.04 high end, or if the stock retests the $52.58 July 2026 low without a corresponding deterioration in earnings. It would downgrade to Sell if gross margin falls back below 12% or if forward EPS estimates drift toward the $5.69 low end, which would push the multiple toward 10x on shrinking earnings. Valuation verdict: fairly valued to modestly undervalued on normalized earnings, but not a bargain on trailing fundamentals — the market is pricing a trough, and the question is whether the trough is behind the company.

Sign up to view all

LYB 12-Month Price Forecast

The forward view is genuinely balanced: LYB trades at ~9.1x forward earnings and 0.46x sales, levels that price in a trough, while Q3 2026 delivered $758 million of net income and $1.413 billion of free cash flow that suggest the trough may be behind the company. Against that, trailing profitability is still negative (EPS -$0.053, ROE -7.37%), gross margin has swung 12 points in three quarters, and the February 2026 dividend cut plus the March 2026 naphtha shock show how fragile the recovery is. Analyst sentiment is split — Wells Fargo and RBC constructive, UBS, Citigroup and Barclays neutral, with one downgrade and no upgrades — and the absence of a consensus target means the stock lacks a valuation anchor. I would upgrade to bullish if gross margin holds above 17% for two consecutive quarters and forward EPS estimates move toward $7.04, or if the stock retests $52.58 without earnings deterioration. I would downgrade to bearish if gross margin falls back below 12% or if estimates drift toward the $5.69 low end, which would make the current multiple a value trap rather than a discount.

Historical Price
Current Price $55.84
Average Target $55.84
High Target $64.22
Low Target $47.46

Wall Street consensus

Thirteen analysts cover LYB, and the institutional ratings flow is decidedly mixed: recent actions include Wells Fargo at Overweight and RBC Capital at Outperform, alongside UBS, Citigroup and Barclays at Neutral or Equal Weight, and Citigroup downgraded from Buy to Neutral on 2026-09-30. No explicit consensus price target is provided in the data, so implied upside cannot be calculated directly; however, the consensus forward EPS estimate of $6.394 (range $5.692 to $7.037) against the $58.46 price implies roughly 9.1x forward earnings, and the absence of a published average target means sentiment should be characterized as cautiously neutral-to-constructive rather than decisively bullish. The distribution skews toward Hold/Equal Weight, consistent with a stock whose 33.65% one-year gain has already captured much of the recovery thesis.\n\nThe estimate range is wide — forward EPS spans $5.69 to $7.04, a roughly 24% spread, and revenue estimates range from $25.38 billion to $38.20 billion around a $31.92 billion average, a spread of more than 50% that signals high uncertainty about the pace of the chemical cycle. The high end of the EPS range likely assumes margin normalization, stable feedstock costs and a resolution of Middle Eastern supply disruptions, while the low end prices in continued naphtha cost pressure, weak global polyolefin demand and further margin compression. The recent pattern of reiterated ratings with a single downgrade (Citigroup) and no upgrades suggests analysts are in a wait-and-see posture; the wide dispersion in both earnings and revenue estimates, combined with the stock's -36.17% max drawdown, argues for treating consensus numbers as a range rather than a point forecast.

Drowning in data?

Find the real signal!

Bulls vs Bears: LYB Investment Factors

The evidence currently favors the bear side on near-term momentum but the bull side on valuation and earnings trajectory: trailing profitability is still negative (EPS -$0.053, ROE -7.37%) and the stock has lost 14.16% over three months with -9.91% relative strength, yet Q3 2026 delivered $758 million of net income and $1.413 billion of free cash flow at just 9.1x forward earnings and 0.46x sales. The single most important tension is whether the Q3 profit recovery is the start of a genuine cyclical upturn or a temporary spike before another leg down — if gross margins hold near the high-teens and forward EPS of $6.39 proves achievable, the stock is deeply undervalued; if margins roll back toward Q1's 9.74%, the 9.1x multiple is a value trap. The February 2026 dividend cut and the naphtha supply shock are the clearest signals that management and the market still see fragility, while the 33.65% one-year gain suggests much of the recovery hope is already priced. With 13 analysts split between Overweight/Outperform and Neutral and no published consensus target, sentiment is best characterized as cautiously neutral-to-constructive rather than decisively bullish.

Bullish

  • Sharp sequential profit recovery: Q3 2026 net income of $758 million (EPS $2.33) marked a fifth consecutive quarter of improvement from Q1 2026's $125 million and Q2 2026's $559 million, and a dramatic reversal from the -$892 million loss in Q3 2025. Operating income swung from -$731 million a year ago to $1.067 billion, showing operating leverage is working as volumes and spreads normalize.
  • Deep valuation on normalized earnings: At $58.46 against consensus forward EPS of $6.394, LYB trades at roughly 9.1x forward earnings, while price-to-sales of 0.46x and price-to-book of 1.38x sit at the bottom of the stock's own multi-year band (PS was 3.60x in Q1 2026, PB 2.58x). The market is pricing a trough, not a recovery, leaving room for re-rating if margins hold.
  • Strong cash generation and liquidity: Q3 2026 operating cash flow of $1.716 billion and free cash flow of $1.413 billion against a $13.9 billion market cap imply a roughly 17% annualized FCF yield, with $3.235 billion of cash and a 1.77 current ratio. Dividends of $224 million per quarter are comfortably covered by Q3 cash flow even after the February 2026 cut.
  • Revenue returning to growth: Q3 2026 revenue of $8.499 billion grew 9.99% year-over-year versus $7.727 billion, and the $31.92 billion consensus revenue average implies continued recovery. The portfolio spans polyethylene ($1.908 billion), oxyfuels ($1.887 billion) and polypropylene ($1.399 billion), giving diversified exposure to a cyclical upturn.

Bearish

  • Dividend cut signals deep distress: The February 2026 dividend reduction, described in press coverage as coming amid 'one of the longest downturns in chemical industry' history, removed a key income pillar and signaled management prioritized balance-sheet defense over shareholder returns. The payout ratio of -2.37 reflects negative trailing earnings, so the current 12.65% yield is not a reliable income stream.
  • Trailing profitability still negative: Trailing EPS is -$0.053 with a -2.46% net margin, -1.08% operating margin and -7.37% ROE, and the trailing PE of -18.43x is meaningless. Even Q3's 17.6% gross margin is below mid-cycle norms for a commodity chemical producer, and gross margin has been volatile (9.74% Q1, 22.21% Q2, 17.60% Q3).
  • Momentum has broken down: Despite a 33.65% one-year gain, the stock is down 8.24% over one month and 14.16% over three months versus the S&P 500's -4.73% and -4.25%, producing relative strength of -3.51% and -9.91%. The latest session fell 3.67% on 5.3 million shares, and the 6-month change of -16.15% versus -2.07% for the index confirms a failed rally.
  • Leverage and cyclical fragility: Debt-to-equity of 1.58x and an EV/EBITDA of 22.33x (elevated versus the 19.65x recorded at Q3 2026) show EBITDA remains depressed relative to enterprise value. Free cash flow is lumpy — -$538 million in Q1 2026 and $482 million in Q2 before Q3's $1.413 billion — so the headline FCF yield is inflated by working-capital swings.

LYB Technical Analysis

LYB is in a recovery uptrend that has recently rolled over into a corrective phase: the stock is up 33.65% over the past year and 31.70% year-to-date, dramatically outperforming the S&P 500's 10.62% and 7.08% respective gains, with relative strength of +23.03% over 12 months and +24.62% YTD. However, the current price of $58.46 sits in the lower portion of the trailing 180-day range, roughly 15% below the $68.64 close on 2026-10-30 and about 9% above the $52.58 low set on 2026-07-01, placing it near the lower third of its recent range. That positioning signals a momentum-driven stock that has surrendered most of its autumn advance rather than one pressing against highs, and the -36.17% max drawdown underscores how violently this name can retrace.\n\nShort-term momentum has deteriorated sharply and now diverges from the longer-term trend: the stock is down 8.24% over one month and 14.16% over three months, versus a 33.65% one-year gain, while the S&P 500 fell only 4.73% and 4.25% over the same windows, producing relative strength of -3.51% (1M) and -9.91% (3M). The latest session compounded the weakness with a -3.67% drop on volume of roughly 5.3 million shares, and the 6-month change of -16.15% versus the index's -2.07% confirms the stock has been a persistent laggard since late spring despite its strong 12-month headline. This pattern — strong 1-year, negative 3- and 6-month, and accelerating 1-month weakness — is characteristic of a failed rally and mean reversion rather than a healthy consolidation, and the absence of RSI data limits confirmation of oversold conditions.\n\nKey technical levels are well defined by the 180-day price history: support clusters at the July low of $52.58 and secondarily around $55.73-$56.35, while resistance sits at the October high of $68.64 and the August swing high of $68.10. A decisive break below $52.58 would signal that the entire 2026 recovery has failed and likely open a retest of lower levels, whereas reclaiming $68.64 would confirm a new leg higher and validate the bullish 12-month trend. Beta is not available in the provided data, but the -36.17% max drawdown and the stock's 3.5-point monthly underperformance versus SPY imply above-market volatility, warranting smaller position sizing and wider stops for risk management.

Beta

—

—

Max Drawdown

-36.2%

Largest decline past year

52-Week Range

—

Price range past year

Annual Return

+31.2%

Cumulative gain past year

PeriodLYB ReturnS&P 500
1m-11.7%-9.7%
3m-17.3%-9.9%
6m-19.9%-7.5%
1y+31.2%+4.7%
ytd+25.8%+1.2%

Bobby - Your AI Investment Partner

Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions

LYB Fundamental Analysis

Revenue is recovering but unevenly: Q3 2026 revenue of $8.499 billion grew 9.99% year-over-year versus $7.727 billion in Q3 2025, yet declined sequentially from Q2 2026's $9.177 billion and Q1 2026's $7.197 billion, reflecting a lumpy quarterly pattern rather than a smooth acceleration. The year-over-year comparison is flattered by an exceptionally weak prior-year base (Q3 2025 revenue of $7.727 billion carried a -11.5% net margin), and the segment mix shows polyethylene at $1.908 billion, oxyfuels at $1.887 billion, polypropylene at $1.399 billion, olefins and co-products at $1.257 billion, compounding and solutions at $923 million and intermediates and derivatives at $425 million — a portfolio still heavily weighted toward commodity polyolefins and fuel-related products where pricing power is limited. The growth trend implies cyclical stabilization rather than structural expansion, leaving the investment case hostage to industry operating rates and feedstock spreads.\n\nProfitability has swung from deeply negative to solidly positive within four quarters: Q3 2026 net income reached $758 million (EPS $2.33) on a 17.6% gross margin and 12.55% operating margin, a dramatic reversal from Q3 2025's -$892 million loss (EPS -$2.77) and -4.76% EBITDA margin, and a sequential improvement from Q2 2026's $559 million net income (EPS $1.72) and Q1 2026's $125 million (EPS $0.39). Gross margin, however, has been volatile — 9.74% in Q1 2026, 22.21% in Q2, 17.60% in Q3 — and the trailing-12-month figures remain impaired, with a -2.46% net margin, -1.08% operating margin and -7.37% ROE, plus a -$0.053 trailing EPS. For a commodity chemicals producer, mid-teens gross margins are below mid-cycle norms, so the current profitability reflects a cyclical trough-recovery rather than durable margin expansion.\n\nThe balance sheet is serviceable but leveraged: debt-to-equity stands at 1.58x, the current ratio is 1.77, and cash of $3.235 billion at Q3 2026 provides reasonable liquidity against $1.716 billion of quarterly operating cash flow and $1.413 billion of free cash flow. TTM free cash flow of $2.414 billion against a $13.9 billion market cap implies a roughly 17% FCF yield, though this is inflated by working-capital swings — Q1 2026 FCF was -$538 million and Q2 only $482 million before Q3's $1.413 billion — and capital expenditure of $303 million in Q3 remains modest relative to depreciation of $370 million. Dividends of $224 million per quarter are comfortably covered by Q3 cash flow, but the February 2026 cut was a clear signal that management prioritized balance-sheet defense over shareholder returns during the downturn.

Quarterly Revenue

$8.5B

2026-09

Revenue YoY Growth

+10.0%

YoY Comparison

Gross Margin

17.6%

Latest Quarter

Free Cash Flow

$2.4B

Last 12 Months

Revenue & Net Income Trends (2 Years)

Revenue Breakdown

Compounding and solutions
Intermediates and Derivatives
Olefins And Co Products
Oxyfuels And Related Products
Polyethylene
Polypropylene

Open an Account, get $2 TSLA now!

Valuation Analysis: Is LYB Overvalued?

Because trailing net income is negative (EPS of -$0.053, trailing PE of -18.43x), the PE ratio is not meaningful and I have selected the price-to-sales ratio as the primary metric, supplemented by EV/EBITDA and price-to-book. LYB trades at 0.46x sales, 1.38x book and 22.33x EV/EBITDA, while the forward PE of 0.12x is a data artifact that should be disregarded; the more informative signal is the consensus forward EPS of $6.39, which against the $58.46 price implies roughly 9.1x forward earnings — a low multiple that prices in skepticism about the durability of the current profit recovery. The gap between trough trailing earnings and a mid-single-digit forward multiple reflects the market's expectation of cyclical normalization rather than structural growth.\n\nPeer comparison is constrained because the provided valuation dataset does not include industry averages, so a precise premium or discount cannot be quantified; however, the absolute multiples are instructive. A 0.46x sales multiple and 1.38x book value are consistent with a deep-cyclical commodity chemical producer at a discount to the broader market, while the 22.33x EV/EBITDA is elevated relative to the 19.65x enterprise-value multiple recorded at Q3 2026 and the 13.14x price-to-free-cash-flow ratio, suggesting EBITDA is still depressed relative to enterprise value. The 9.0% gross margin and -2.46% net margin are well below what a specialty chemicals franchise would command, which argues that any discount to peers is at least partly justified by inferior current profitability rather than pure mispricing.\n\nHistorically, LYB's valuation has compressed dramatically: the PE ratio was 6.17x at Q3 2026, 7.65x at Q2 2026 and 53.0x at Q1 2026, while the price-to-sales ratio has fallen from 3.60x in Q1 2026 to 2.18x in Q3 2026 and now 0.46x on the current dataset, and price-to-book has slid from 2.58x in Q1 2026 to 1.38x. The stock is therefore near the bottom of its own multi-year valuation band on book and sales, which can signal either a genuine value opportunity or fundamental deterioration — and given the dividend cut, negative trailing earnings and the naphtha supply shock, the market is currently pricing the latter. Re-rating would require sustained margin recovery toward mid-cycle levels and evidence that the industry downturn has truly ended.

PE

-18.4x

Latest Quarter

vs. Historical

Low-End

5-Year PE Range 4x~33x

vs. Industry Avg

31.4x

Industry PE ~31.4x*

EV/EBITDA

22.3x

Enterprise Value Multiple

Investment Risk Disclosure

Financial and operational risks center on a still-impaired earnings base and lumpy cash generation. Trailing EPS of -$0.053, a -2.46% net margin and -7.37% ROE mean the company has not yet demonstrated durable profitability, and gross margin swung from 9.74% in Q1 2026 to 22.21% in Q2 and 17.60% in Q3 — a 12-point range in three quarters. Debt-to-equity of 1.58x and an EV/EBITDA of 22.33x against a 19.65x enterprise-value multiple at Q3 2026 show EBITDA is depressed relative to the capital structure, while free cash flow of -$538 million in Q1 2026 and only $482 million in Q2 before Q3's $1.413 billion confirms heavy working-capital dependence. The February 2026 dividend cut, with a payout ratio of -2.37, is direct evidence that cash returns are not secure if the cycle rolls over again. Market and competitive risks stem from the stock's commodity identity and its recent momentum breakdown. LYB is a cost-curve polyolefin producer with a 9.0% gross margin and no branded moat, so pricing is set by global operating rates and feedstock spreads rather than company execution; the March 2026 Middle Eastern naphtha disruption tied to the Iran/Hormuz conflict demonstrated how quickly input costs can spike, and the April 2026 Hormuz reopening showed the reverse volatility. The stock has underperformed the S&P 500 by 9.91% over three months and 14.08% over six months despite a 33.65% one-year gain, and the -36.17% max drawdown illustrates severe drawdown risk; with beta unavailable but the 3.5-point monthly underperformance implying above-market volatility, position sizing should be conservative. The worst-case scenario is a renewed downturn in global petrochemical demand combined with a fresh feedstock shock: gross margins revert toward Q1 2026's 9.74%, forward EPS of $6.39 proves unreachable and drifts toward the $5.69 low end, and the stock retests its July 2026 low of $52.58 — roughly -10% from the current $58.46 — with a break below that level opening a deeper retest given the -36.17% historical max drawdown. In a more severe replay of the 2025 trough, when Q3 2025 posted a -$892 million net loss, a move toward the low-$40s would represent a loss of roughly 25-30% from current levels.

FAQ

Ranked by severity: first, cyclical earnings risk — gross margin swung from 9.74% in Q1 2026 to 22.21% in Q2 and 17.60% in Q3, and trailing EPS of -$0.053 with a -7.37% ROE shows profitability is not yet durable, so a renewed polyolefin downturn could quickly erase the recovery. Second, feedstock and geopolitical risk — the March 2026 Middle Eastern naphtha disruption tied to the Iran/Hormuz conflict pressured production costs, and although Hormuz reopened in April 2026, a repeat spike would hit margins faster than product prices can adjust. Third, balance-sheet and capital-return risk — debt-to-equity of 1.58x, EV/EBITDA of 22.33x and a payout ratio of -2.37 mean the 12.65% dividend yield is not secure, as the February 2026 cut already demonstrated. Fourth, momentum and valuation-compression risk — the stock is down 8.24% over one month and 14.16% over three months with -9.91% relative strength versus the S&P 500, and the -36.17% max drawdown illustrates how violently this name can retrace if the cycle thesis fails.

The 12-month view is split three ways: a 50% base case of $58-$68, a 30% bull case of $72-$80 and a 20% bear case of $42-$53. The base case assumes forward EPS near the $6.394 consensus and a 9-10.5x multiple, leaving the stock oscillating with quarterly prints around the current $58.46 and the October 2026 high of $68.64. The bull case requires global polyolefin operating rates to tighten and forward EPS to reach the $7.04 high end, with a mid-cycle 10-11x multiple implying $70-$77 and a re-rating beyond the October high. The bear case assumes margins revert toward Q1 2026's 9.74%, EPS drifts toward the $5.69 low end, and the stock retests the $52.58 July low before falling into the low-$40s in a severe replay of the 2025 trough. The base case is most likely because the recovery is real but gradual, and the key assumption behind it is that gross margin averages in the mid-teens without a return to trough levels.

On normalized earnings the stock looks modestly undervalued, but on trailing fundamentals it is not a bargain. Trailing PE of -18.43x is meaningless given negative EPS, so the relevant metrics are 0.46x sales, 1.38x book and 22.33x EV/EBITDA, plus roughly 9.1x the $6.394 consensus forward EPS. Those multiples sit at the bottom of the stock's own multi-year band — price-to-sales has fallen from 3.60x in Q1 2026 to 2.18x in Q3 2026 and now 0.46x, and price-to-book from 2.58x to 1.38x — which can signal either genuine mispricing or fundamental deterioration. The elevated 22.33x EV/EBITDA versus 19.65x at Q3 2026 shows EBITDA is still depressed relative to enterprise value, and a 9.0% gross margin and -2.46% net margin are well below what a specialty chemicals franchise would command. The market is therefore pricing a trough and demanding proof that the Q3 profit recovery is durable; if gross margin holds in the high-teens and forward EPS of $6.39 is achieved, the stock is cheap, but if margins roll back toward Q1's 9.74%, the discount is deserved.

The risk/reward is balanced rather than compelling at $58.46. On the positive side, the stock trades at roughly 9.1x the $6.394 consensus forward EPS, 0.46x sales and 1.38x book, and Q3 2026 delivered $758 million of net income and $1.413 billion of free cash flow — a fifth straight quarter of sequential improvement from Q1 2026's $125 million and a reversal of the -$892 million Q3 2025 loss. On the negative side, trailing EPS is -$0.053 with a -2.46% net margin, the February 2026 dividend was cut, and the stock is down 14.16% over three months versus the S&P 500's -4.25%, with a -36.17% historical max drawdown showing how far a cyclical reversal can take it. With 13 analysts split between Overweight/Outperform and Neutral and no published consensus target, there is no clear valuation anchor. It is a reasonable buy only for patient, valuation-focused investors who can tolerate a retest of the $52.58 July low (about -10%) or the low-$40s in a severe downturn, and who size positions accordingly; it is not a good buy for income seekers or those needing near-term momentum.

LYB is better suited to a medium-to-long-term holding period of at least 18-24 months than to short-term trading. It is a deep-cyclical commodity chemical producer whose earnings visibility is low — forward EPS estimates span $5.69-$7.04 (a 24% spread) and revenue estimates span $25.38-$38.20 billion (a >50% spread) — so quarterly prints drive sharp swings rather than smooth trends, as shown by the -3.67% single-session drop on 5.3 million shares and the -36.17% max drawdown. The 33.65% one-year gain against the S&P 500's 10.62% shows the cyclical recovery trade can pay, but the -16.15% six-month change versus -2.07% for the index shows how quickly that lead can erode. The dividend, cut in February 2026 and carrying a payout ratio of -2.37, should not be relied upon as an income stream, which removes the main reason to hold passively through a downturn. A patient investor with a 2-year horizon can accumulate on weakness toward the $52.58 support, but traders should respect the $68.64 resistance and the deteriorating 1- and 3-month momentum.